UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14D-9
(AMENDMENT NO. 1)
Solicitation/Recommendation Statement under
Section 14(d)(4) of the Securities Exchange Act of 1934
EXEGENICS INC.
(Name of Subject Company)
EXEGENICS INC.
(Name of Person Filing Statement)
Common Stock, Par Value $0.01 Per Share
(including the associated share purchase rights)
Series A Convertible Preferred Stock, Par Value $0.01 Per
Share
(Title of Class of Securities)
301610 (Common Stock)
(CUSIP not applicable for Preferred Stock)
(CUSIP Number of Class of Securities)
RONALD L. GOODE, PH.D.
EXEGENICS INC.
2110 RESEARCH ROW
DALLAS, TEXAS 75235
(214) 358-2000
(Name, address and telephone number of person authorized to receive notice and
communications on behalf of the person filing statement)
Copy to:
JOEL I. PAPERNIK, ESQ.
MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C.
666 THIRD AVENUE
24TH FLOOR
NEW YORK, NEW YORK 10017
(212) 935-3000
This Amendment No. 1 amends and supplements the Solicitation/Recommendation Statement on Schedule 14D-9 initially filed with the Securities and Exchange Commission on July 25, 2003 (the "Schedule 14D-9"), by eXegenics Inc., a Delaware corporation ("eXegenics"), relating to the exchange offer made by AVI BioPharma, Inc. (the "Purchaser"), an Oregon corporation, as set forth in a Tender Offer Statement filed by the Purchaser on Schedule TO, dated July 25, 2003 (the "Schedule TO"), for all of the outstanding common stock, par value $0.01 per share, of eXegenics, and Series A Convertible Preferred Stock, par value $0.01 per share of eXegenics (together, the "Shares"), upon the terms and subject to the conditions set forth in the Schedule TO. Unless otherwise indicated, all capitalized terms used but not defined herein shall have the meanings ascribed to them in the Schedule 14D-9.
Item 8. Additional Information.
Item 8 of the Schedule 14D-9 is hereby amended to add the following:
The information set forth in Exhibit 12 filed herewith is incorporated herein by reference.
Item 9 of the Schedule 14D-9 is hereby amended by adding the following thereto:
| Exhibit No. |
|
|
|---|---|---|
| Exhibit 12. | Press Release issued by eXegenics and AVI BioPharma, Inc. on July 29, 2003. |
2
After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
EXEGENICS INC. |
||||
By: |
/s/ RONALD L. GOODE Ronald L. Goode Chairman, Chief Executive Officer and President |
|||
Dated: July 29, 2003
3